EN DE
Watch YSP Southeast Asia Holding Bhd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

YSP Southeast Asia Holding Bhd (7178) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of YSP Southeast Asia Holding Bhd stock MYR 3.88, price MYR 1.95, upside +99.0%, quality 70 out of 100. Rating: strongly undervalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare MY · ISIN MYL7178OO006

YS YSP Southeast Asia Holding Bhd logo Thin data Nov 9, 2026

YSP Southeast Asia Holding Bhd

7178 · KLSE
Meets all rules

The stock costs 50% less than our calculation considers fair.

Fair value 3.88 MYR · Strongly undervalued
Quality 70/100
Low debt
Generates free cash flow
5.6% dividend yield · Well covered
Ranks above peers (11/14)
Even on cautious assumptions the value is 49% above the price (2.91 MYR).
Mixed Growth (revenue 5y +4.2 %/yr in MYR)
Thin margins · 7.3% net margin (TTM)
Narrow moat 42/100 · thin data
Thin data
Watch YSP Southeast Asia Holding Bhd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

2.71 MYR 1.62 MYR Fair Value 3.88 MYR Apr 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

60‑month range 1.62 MYR – 2.71 MYR · fair‑value band 2.91 MYR – 4.83 MYR · the 1.95 MYR price screens below the 3.88 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow YSP Southeast Asia Holding Bhd in your weekly email

Every Wednesday you see whether YSP Southeast Asia Holding Bhd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Y.S.P. Southeast Asia Holding Berhad, together with its subsidiaries, engages in the manufacturing and trading of generic drugs in Malaysia, Singapore, Vietnam, Philippines, Cambodia, Myanmar, Brunei, Indonesia, Thailand, Africa, and internationally.

Show moreShow less

It operates through three segments: Manufacturing, Trading, and Investment Holding. The company manufactures, sells, imports, exports, trades in, and distributes pharmaceutical and veterinary products, pharmaceutical fine chemicals, raw material, health food products, and medical devices.

It also manufactures aquatic, cosmetic, and biotechnology and health products, as well as traditional herbal medicines, food and health supplements, and over-the-counter products; and offers management services.

Y.S.P. Southeast Asia Holding Berhad was founded in 1987 and is headquartered in Kuala Lumpur, Malaysia.

Stock analysis

YSP Southeast Asia Holding Bhd (7178) currently trades at 1.95 MYR, while our model-based Fair Value estimate is 3.88 MYR, implying the stock looks roughly 50% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of 4.33 MYR per share, and 21 of the 25 models we run sit above the 1.95 MYR price.

Bear case: the Dividend Discount group reads lowest at 1.35 MYR, and 4 of the 25 models stay below the price. Data coverage for this calculation is low.

Scenario range: 2.91 MYR (bear) to 4.83 MYR (bull), the price of 1.95 MYR sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

YSP Southeast Asia Holding Bhd reported revenue of 365M MYR in FY2025 versus 282M MYR in FY2021, a compound +6.7%/yr. Reported net income was 25.0M MYR in FY2025, compounding +13.3%/yr from FY2021.

Key figures

Market cap 277M MYR (≈ $68.2M) Micro · P/E ratio 10.3 · P/S ratio 0.75 · EPS (TTM) 0.1900 MYR · Dividend yield 5.6% · Net margin 7.3% · Return on equity 6.4% · Return on assets (EBIT) 8.1% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 8% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 99%, 7178 screens cheaper than that median.

Fair Value models

Bear 2.91 MYR Fair Value 3.88 MYR Bull 4.83 MYR
Price 1.95 MYR · Upside +99.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.0686 MYR per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 3.48 MYR 4.21 MYR 5.03 MYR 82
Growth DCF 3.49 MYR 4.14 MYR 4.83 MYR 80
Owner Earnings 2.06 MYR 2.39 MYR 2.76 MYR 78
All 25 models by family
DCF Models
FCF DCF 3.48 MYR 4.21 MYR 5.03 MYR 82
Owner Earnings 2.06 MYR 2.39 MYR 2.76 MYR 78
5Y Revenue Exit 3.32 MYR 4.37 MYR 5.65 MYR 74
5Y EBITDA Exit 3.97 MYR 5.54 MYR 7.29 MYR 76
5Y P/E Exit 3.45 MYR 4.60 MYR 5.74 MYR 72
10Y Revenue Exit 3.32 MYR 4.15 MYR 5.16 MYR 68
10Y EBITDA Exit 3.70 MYR 4.79 MYR 6.12 MYR 70
10Y P/E Exit 3.43 MYR 4.28 MYR 5.21 MYR 65
Earnings-Based
Graham-Dodd 1.20 MYR 3.02 MYR 3.93 MYR 65
PEG = 1.0 0.5600 MYR 0.8000 MYR 1.03 MYR 57
EPV 2.03 MYR 2.15 MYR 2.25 MYR 74
Dividend Discount
Gordon GGM 0.9400 MYR 1.42 MYR 1.83 MYR 69
DDM Multi-Stage 0.9400 MYR 1.27 MYR 1.54 MYR 67
Multiples
P/E Multiple 2.91 MYR 3.88 MYR 4.85 MYR 63
P/S Multiple 2.25 MYR 3.00 MYR 3.75 MYR 58
P/B Multiple 2.10 MYR 2.80 MYR 3.51 MYR 55
EV/EBIT 4.32 MYR 5.46 MYR 6.61 MYR 66
EV/EBITDA 4.96 MYR 6.32 MYR 7.68 MYR 67
EV/Revenue 3.33 MYR 4.38 MYR 5.43 MYR 54
Asset-Based
NCAV (Graham) 1.16 MYR 1.76 MYR 2.20 MYR 54
Growth DCF
Growth DCF 3.49 MYR 4.14 MYR 4.83 MYR 80
Rev-Margin DCF 3.32 MYR 4.41 MYR 5.62 MYR 74
Economic Profit
Residual Income 2.03 MYR 2.03 MYR 2.10 MYR 76
ROIC Compounder 2.03 MYR 2.15 MYR 2.25 MYR 72
Growth Earnings
Growth-Adj P/E 2.24 MYR 3.20 MYR 4.16 MYR 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 70/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 42
How much profit the company makes from its sales and capital
Quality Growth 43
Are margins and returns getting better?
Cashflow 79
Do the profits arrive as real cash?
Financial strength 96
Debt, balance sheet and risk of trouble
Investment 86
Does it invest with discipline instead of growing at any price?
Low Volatility 87
How calm the share price moves, does not count
Price momentum 37
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 25
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 61/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−1.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.2%
Start year 2020 (pandemic). Over 10 years: +5.1% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
What shareholders gained per year (last 5 years), in MYR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in MYR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+9.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+4.0%
Dividend (yield on the price)5.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.4.0% vs −2.0%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 11%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−16.8%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Malaysia: IMF forecast 2.0% a year to 2030, 1.8% from 2016 to 2025) that is about −18.4% a year for the price.

Watch 7178, get fair value alerts →

Compare YSP Southeast Asia Holding Bhd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 11/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 70 · Top 25%
Fair Value upside +99.0% · Top 25%
Profitability
Return on equity (12 months) 6.4% · Below median
Return on assets 4.6% · Above median
Net margin (12 months) 7.3% · Below median
Operating margin (12 months) 8.3% · Below median
Growth and dividend
Revenue growth (quarter YoY) 8.5% · Above median
Dividend yield (12 months) 5.6% · Top 25%
Balance sheet
Debt / equity 0.06× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 10.3× · Cheapest 25%
P/B 0.66× · Cheapest 25%
P/S (12 months) 0.75× · Cheapest 25%
Price / free cash flow (fiscal year) 5.5× · Cheapest 25%
EV/EBITDA 2.9× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 15
FUTURE (revenue growth)43 · sector 25
PAST (return on equity)26 · sector 29
HEALTH (low debt)97 · sector 96
DIVIDEND (yield)100 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs 7178
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs 7178
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs 7178
Haleon plc HLN $9.14 $8.61 −6% vs 7178
Merck KGaA MRK €148.75 €109.18 −27% vs 7178
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs 7178
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs 7178
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs 7178
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs 7178
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs 7178

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

YSP Southeast Asia Holding Bhd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "YSP Southeast Asia Holding Bhd Fair Value". https://www.fairvalue-calculator.com/stock/7178

Frequently asked questions

Is YSP Southeast Asia Holding Bhd (7178) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 3.88 MYR versus a price of 1.95 MYR, about +99% upside (undervalued).
What is the fair value of 7178?
Our model-based fair value for YSP Southeast Asia Holding Bhd is 3.88 MYR (as of Nov 9, 2026), built from audited fundamentals. The current price: 1.95 MYR.
What is the quality score of 7178?
YSP Southeast Asia Holding Bhd has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for YSP Southeast Asia Holding Bhd (7178)?
Our model-based price target is the fair value of 3.88 MYR (as of Nov 9, 2026) from 25 valuation models. Cautious scenario 2.91 MYR, optimistic scenario 4.83 MYR. It is a calculation from audited fundamentals, not an analyst target.
What is the YSP Southeast Asia Holding Bhd stock forecast for 2026?
Our models put fair value at 3.88 MYR, about +99% upside versus a price of 1.95 MYR (undervalued). Cautious scenario 2.91 MYR, optimistic scenario 4.83 MYR. The calculation is refreshed regularly with new filings.
What is the revenue of YSP Southeast Asia Holding Bhd (7178)?
YSP Southeast Asia Holding Bhd reported trailing-twelve-month revenue of about 370M MYR (latest available figure, as of Nov 9, 2026).
Does YSP Southeast Asia Holding Bhd pay a dividend?
YSP Southeast Asia Holding Bhd currently shows a dividend yield of 5.64% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of YSP Southeast Asia Holding Bhd (7178) and when is the ex-dividend date?
YSP Southeast Asia Holding Bhd pays a dividend of 0.11 MYR per share a year, a dividend yield of 5.6%. The last ex-dividend date was Jun 26, 2026. A dividend has been paid every year since 2007. The payout ratio is 57.9% of earnings. Free cash flow covers the dividend 3.21 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into YSP Southeast Asia Holding Bhd (7178)?
For today's price to be fair in a discounted-cash-flow model, YSP Southeast Asia Holding Bhd would have to grow free cash flow by -16.8 % per year for five years (discount rate 14.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.2 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 7178 use?
Our models discount YSP Southeast Asia Holding Bhd at 14.1 %: a base by market capitalisation (micro), country premium for Malaysia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For YSP Southeast Asia Holding Bhd that is -16.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (14.1 %) and the same formula as our fair value.
How much growth has YSP Southeast Asia Holding Bhd (7178) delivered so far?
Over the past 5 years revenue at YSP Southeast Asia Holding Bhd grew +4.2 % a year. The price currently implies free-cash-flow growth of -16.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of YSP Southeast Asia Holding Bhd (7178) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into YSP Southeast Asia Holding Bhd (-16.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of YSP Southeast Asia Holding Bhd (7178)?
The free-cash-flow yield on the price is 18.13 %: that much free cash flow YSP Southeast Asia Holding Bhd produces per unit of market value. When it exceeds the discount rate of our models (14.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of YSP Southeast Asia Holding Bhd (7178)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For YSP Southeast Asia Holding Bhd it is 3.88 MYR per share (as of Nov 9, 2026), against a price of 1.95 MYR. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is YSP Southeast Asia Holding Bhd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 7178 trades below its calculated fair value: price 1.95 MYR, fair value 3.88 MYR, a gap of about +99% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 7178?
No. The price is what the market pays today (1.95 MYR); the fair value is what the company's own numbers justify (3.88 MYR). For YSP Southeast Asia Holding Bhd the two are 1.93 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is YSP Southeast Asia Holding Bhd worth?
The market values YSP Southeast Asia Holding Bhd at about 277M MYR (market capitalisation, as of Nov 9, 2026). Per share that is 1.95 MYR; our models calculate a fair value of 3.88 MYR per share.
What do the bullish and bearish scenarios say about 7178?
Our models span a range for YSP Southeast Asia Holding Bhd: cautious scenario 2.91 MYR, base 3.88 MYR, optimistic 4.83 MYR per share (as of Nov 9, 2026, price 1.95 MYR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 7178?
YSP Southeast Asia Holding Bhd trades at a price-to-earnings ratio of 10.3 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 3.88 MYR is built from several models across several years. Other multiples: P/B 0.7, P/S 0.7, EV/EBITDA 2.9.
How solid is the balance sheet of YSP Southeast Asia Holding Bhd (7178)?
Balance-sheet figures for YSP Southeast Asia Holding Bhd (as of Nov 9, 2026): return on equity 6.4%, debt of 0.06 per unit of equity. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is 7178 from its 52-week high?
YSP Southeast Asia Holding Bhd trades at 1.95 MYR, about 8% below its 52-week high of 2.13 MYR and 2% above the low of 1.91 MYR (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 3.88 MYR is for.
Which stocks are comparable to YSP Southeast Asia Holding Bhd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is YSP Southeast Asia Holding Bhd stock attractive at the current price?
The data as of Nov 9, 2026: price 1.95 MYR, calculated fair value 3.88 MYR (+99%), Quality Score 70/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 7178 calculated?
We run YSP Southeast Asia Holding Bhd through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 3.88 MYR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. YSP Southeast Asia Holding Bhd currently trades 50% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of YSP Southeast Asia Holding Bhd (7178)?
The closing price on Nov 6, 2026 was 1.95 MYR. Our model-based fair value is 3.88 MYR, about +99% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with YSP Southeast Asia Holding Bhd right now?
The price is below even our cautious bear case (2.91 MYR). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (70/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of YSP Southeast Asia Holding Bhd

How large is the market capitalisation of YSP Southeast Asia Holding Bhd (7178)?
The market capitalisation of YSP Southeast Asia Holding Bhd is 277M MYR (≈ $68.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of YSP Southeast Asia Holding Bhd (7178)?
The price-to-sales ratio of YSP Southeast Asia Holding Bhd is 0.75 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of YSP Southeast Asia Holding Bhd (7178)?
Earnings per share at YSP Southeast Asia Holding Bhd are 0.1900 MYR (price ÷ EPS = P/E 10.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of YSP Southeast Asia Holding Bhd (7178)?
The dividend yield of YSP Southeast Asia Holding Bhd is 5.6% (payout 57.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of YSP Southeast Asia Holding Bhd (7178)?
The net margin of YSP Southeast Asia Holding Bhd is 7.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of YSP Southeast Asia Holding Bhd (7178)?
The return on equity (ROE) of YSP Southeast Asia Holding Bhd is 6.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of YSP Southeast Asia Holding Bhd (7178)?
On an EBIT basis the return on assets of YSP Southeast Asia Holding Bhd is 8.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of YSP Southeast Asia Holding Bhd (7178)?
The operating margin of YSP Southeast Asia Holding Bhd is 8.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at YSP Southeast Asia Holding Bhd (7178)?
Revenue at YSP Southeast Asia Holding Bhd is growing +8.5% versus a year earlier (3y avg +3.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at YSP Southeast Asia Holding Bhd (7178)?
Earnings per share at YSP Southeast Asia Holding Bhd are growing +471% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch YSP Southeast Asia Holding Bhd in the live analysis

One click puts YSP Southeast Asia Holding Bhd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.